Kyto Technology & Life Science, Inc. (KBPH) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
13050 PALOMA ROAD LOS ALTOS HILLS, CA 94022 |
| State of Incorp. | DE |
| Fiscal Year End | March 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2021 | 3/31/2020 | 3/31/2019 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 34 | 94 | |||
| Cash and cash equivalents | 34 | 94 | |||
| Receivables | 1 | 1 | |||
| Total current assets: | 34 | 95 | |||
| Noncurrent Assets | |||||
| Long-term investments and receivables | 2,665 | 1,498 | |||
| Long-term investments | 2,665 | 1,498 | |||
| Deferred costs | |||||
| Total noncurrent assets: | 2,665 | 1,498 | |||
| Other undisclosed assets | |||||
| TOTAL ASSETS: | 2,700 | 1,593 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities, including: | 26 | 22 | |||
| Other undisclosed accounts payable and accrued liabilities | 26 | 22 | |||
| Due to related parties | 6 | 7 | |||
| Other undisclosed current liabilities | |||||
| Total current liabilities: | 32 | 29 | |||
| Noncurrent Liabilities | |||||
| Total liabilities: | 32 | 29 | |||
| Equity | |||||
| Equity, attributable to parent, including: | 2,668 | 1,564 | |||
| Common stock | 58 | 1 | |||
| Additional paid in capital | 35,943 | 31,562 | |||
| Accumulated other comprehensive loss | (33,384) | (32,611) | |||
| Other undisclosed equity, attributable to parent | 50 | 2,613 | |||
| Total equity: | 2,668 | 1,564 | |||
| TOTAL LIABILITIES AND EQUITY: | 2,700 | 1,593 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2021 | 3/31/2020 | 3/31/2019 | ||
|---|---|---|---|---|
| Revenues | 14 | 9 | ||
| Other undisclosed gross profit | ||||
| Gross profit: | 14 | 9 | ||
| Operating expenses | (788) | (239) | ||
| Operating loss: | (773) | (230) | ||
| Nonoperating income (Investment Income, Nonoperating) | ||||
| Interest and debt expense | (0) | |||
| Loss from continuing operations: | (773) | (230) | ||
| Loss before gain (loss) on sale of properties: | (773) | (230) | ||
| Other undisclosed net income | ||||
| Net income (loss) available to common stockholders, diluted: | (773) | (230) | ||
Comprehensive Income ($ in thousands)
| 3/31/2021 | 3/31/2020 | 3/31/2019 | ||
|---|---|---|---|---|
| Net income (loss): | (773) | (230) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (773) | (230) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.